Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.65 |
| ▸ | CA1 | P00915 | 15/20 | 0.65 |
| ▸ | MMP1 | P03956 | 6/20 | 0.65 |
| ▸ | MMP2 | P08253 | 6/20 | 0.65 |
| ▸ | MMP9 | P14780 | 6/20 | 0.65 |
| ▸ | MMP8 | P22894 | 6/20 | 0.65 |
| ▸ | MMP13 | P45452 | 6/20 | 0.65 |
| ▸ | F2 | P00734 | 4/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20094836 | 1.00 | CA2 (0.65) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL20094834 | 1.00 | CA2 (0.65) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL20094835 | 1.00 | CA2 (0.65) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2233124 | 0.98 | CA2 (0.64) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2296771 | 0.95 | CA2 (0.61) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2289716 | 0.95 | CA2 (0.61) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2294989 | 0.95 | CA2 (0.61) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2229488 | 0.91 | CA2 (0.54) | CA2CA1MMP1MMP2MMP9 | |
| Ammonia Solution, Strong SCHEMBL29779978 | 0.88 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL7797690 | 0.88 | CA2 (0.67) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345657-B2 | Sulfamic acid derivatives and processes for their preparation | HYDRO-QUEBEC (CA) | 2022-05-31 | — | — | US | disclosed |
| US-20200181071-A1 | SULFAMIC ACID DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | HYDRO-QUéBEC (CA) | 2020-06-11 | — | — | US | disclosed |
| WO-2018072024-A1 | SULPHAMIC ACID DERIVATIVES AND PRODUCTION METHODS THEREOF | HYDRO-QUéBEC (CA) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345657-B2 | Sulfamic acid derivatives and processes for their preparation | STS, SCLY, MPST | CA2 155/4885CA1 16/4885MMP1 1754/4885 |
| US-20200181071-A1 | SULFAMIC ACID DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | STS, SCLY, MPST | CA2 155/4885CA1 16/4885MMP1 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.